Linvoseltamab

Lynozyfic 5 MG Concentrado Para Solucion Para Perfusion

5 mg concentrado para solución para perfusiónSpainAuthorisedAuthorised 16 Dec 2025

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

LynozyficEuropean UnionAuthorised

LynozyficEuropean Union · Regeneron Ireland Designated Activity Company (DAC)Same brand
LynozyficCroatiaSame brand
LynozyficItaly · Concentrato per soluzione per infusione · Regeneron Ireland Designated Activity Company (Dac)Same brand
LYNOZYFIC 200 mg concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · Regeneron Ireland Designated Activity CompanySame brand
LYNOZYFIC 5 mg concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · Regeneron Ireland Designated Activity CompanySame brand

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Linvoseltamab

Lynozyfic 5 MG Concentrado Para Solucion Para Perfusion

5 mg concentrado para solución para perfusiónSpainAuthorisedAuthorised 16 Dec 2025

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

LynozyficEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

LynozyficUnited States · 200MG/10ML · Injection · Regeneron Pharmaceuticals, Inc.

LynozyficUnited States · 5MG/2ML · solution · Rengeneron Pharmaceuticals, INC.

Packs

Pack	Code	Status
LYNOZYFIC 5 MG CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial de 2,5 ml	769508

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Linvoseltamab
Strength: 5 mg
Dosage form: concentrado para solución para perfusión
Route: vía intravenosa
Register: Spain (AEMPS)
Status: Authorised
Status in the register: Autorizado, no comercializado
Authorised: 16 Dec 2025
Registration: 1251917001
Marketing authorisation holder: Regeneron Ireland Designated Activity Company
Procedure: EU centralised
Supply: Uso Hospitalario
EU number: EU/1/25/1917